无聚合物与 durable 聚合物药物洗脱支架10年随机试验结果
ISAR-TEST-5试验将3002例冠心病患者随机分配至无聚合物西罗莫司和普罗布考洗脱支架组(n=2002)或 durable 聚合物佐他莫司洗脱支架组(n=1000),随访10年。两组DOCE(43.8% vs 43.0%,HR 1.01,95%CI 0.89-1.14,p=0.90)和POCE(66.2% vs 67.7%,HR 0.94,95%CI 0.86-1.04,p=0.22)均无显著差异,支架血栓发生率低且相当(1.6% vs 1.9%,HR 0.85,95%CI 0.46-1.54,p=0.58)。
要点
- 10年随访无聚合物与durable聚合物DES的DOCE和POCE无差异。
- 两组支架内血栓发生率均低且相当(1.6% vs 1.9%)。
- 长期随访中总体不良临床事件发生率较高。
核心结论
- 10年随访显示无聚合物与durable聚合物DES在临床结局上无显著差异,支架血栓发生率低且相当,但长期不良事件发生率较高。
研究设计与样本
- ISAR-TEST-5为随机对照试验,共纳入3002例冠心病患者,随机分配至无聚合物西罗莫司和普罗布考洗脱支架组(n=2002)或durable聚合物佐他莫司洗脱支架组(n=1000),随访10年。
主要发现
- 10年时63.9%患者存活,中位年龄67.8岁。
- DOCE发生率无聚合物组43.8% vs durable聚合物组43.0%(HR 1.01,95%CI 0.89-1.14,p=0.90)。
- POCE发生率66.2% vs 67.7%(HR 0.94,95%CI 0.86-1.04,p=0.22)。
- 明确/可能支架血栓发生率1.6% vs 1.9%(HR 0.85,95%CI 0.46-1.54,p=0.58)。
- 复合终点各单独组分发生率两组相当。
临床怎么用
- 对于接受DES治疗的冠心病患者,选择无聚合物或durable聚合物支架时,10年长期结局相似,支架血栓风险均低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcome data after extended long-term follow-up of patients with coronary artery disease treated with drug-eluting stents (DES) in randomized clinical trials are scant. OBJECTIVES: Performance differences among devices may be expected to emerge over time depending on whether stenting is done with polymer-free or durable polymer DES. This study assessed the 10-year outcomes of patients enrolled in the ISAR-TEST-5 (Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents) trial. METHODS: A total of 3,002 patients were randomized to treatment with either polymer-free sirolimus- and probucol-eluting stents (n = 2,002) or durable polymer zotarolimus-eluting stents (n = 1,000). The primary endpoint was the composite of cardiac death, target vessel-related myocardial infarction, or target lesion revascularization (a device-oriented composite endpoint [DOCE]). Additional endpoints of interest were the patient-oriented composite endpoint (POCE), including all-cause death, any myocardial infarction, or any revascularization; individual components of the composite endpoints; and definite or probable stent thrombosis. RESULTS: The median age of the patients at randomization was 67.8 years. At 10 years, 63.9% of patients were alive. The rates of DOCE and POCE were high in both groups with no difference in the incidence between polymer-free sirolimus- and probucol-eluting stents and durable polymer zotarolimus-eluting stents (DOCE: 43.8% vs. 43.0%, respectively; hazard ratio: 1.01; 95% confidence interval [CI]: 0.89 to 1.14; p = 0.90; POCE: 66.2% vs. 67.7%, respectively; hazard ratio: 0.94; 95% CI: 0.86 to 1.04; p = 0.22). The rates of the individual components of the composite endpoints were comparable in both groups. The incidence of definite/probable stent thrombosis over 10 years was low and comparable in both groups (1.6% vs. 1.9%; hazard ratio: 0.85; 95% CI: 0.46 to 1.54; p = 0.58). CONCLUSIONS: At 10 years, there were no measurable differences in outcomes between patients treated with polymer-free versus durable polymer DES. The incidence of stent thrombosis was low and comparable in both groups. High overall adverse clinical event rates were observed during extended follow-up. (Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents [ISAR-TEST-5]; NCT00598533).
引用
- Kufner S, Ernst M, Cassese S, et al. 10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. J Am Coll Cardiol. 2020. PMID: 32646563. doi:10.1016/j.jacc.2020.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。